Payment overview · 2025
General Payments
$768.47
28 reported records · 9 companies
Healthcare provider profile · identity verified
In Kwon Park, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKEWOOD, WA · NPI 1255588679
Verified facts
What the public records show
CMS Open Payments records show In Kwon Park, MD received $768.47 in general payments during 2025 across 28 reported records.
Phathom Pharmaceuticals, Inc. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $222.45 | 28.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.58 | 17.8% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.67 | 14.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.10 | 9.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.31 | 9.2% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $58.73 | 7.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $48.41 | 6.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.72 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.50 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $768.47 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $222.45 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $136.58 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $136.58 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.67 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.10 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.31 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $58.73 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.42 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $48.41 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 241 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 340 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
241 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
340 | 76 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1360 | 372 |
| Amlodipine Besylate | Amlodipine Besylate | 732 | 183 |
| Losartan Potassium | Losartan Potassium | 611 | 149 |
| Omeprazole | Omeprazole | 547 | 145 |
| Metformin Hcl | Metformin Hcl | 384 | 99 |
| Jardiance | Empagliflozin | 340 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 80 |
| Alendronate Sodium | Alendronate Sodium | 318 | 92 |
| Metformin Hcl Er | Metformin Hcl | 313 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 70 |
| Donepezil Hcl | Donepezil Hcl | 265 | 57 |
| Meloxicam | Meloxicam | 263 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 255 | 100 |
| Creon | Lipase/Protease/Amylase | 241 | 44 |
| Lidocaine | Lidocaine | 222 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 53 |
| Famotidine | Famotidine | 213 | 50 |
| Montelukast Sodium | Montelukast Sodium | 206 | 58 |
| Lisinopril | Lisinopril | 194 | 47 |
| Simvastatin | Simvastatin | 187 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 181 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 37 |
| Glipizide Er | Glipizide | 166 | 32 |
| Finasteride | Finasteride | 160 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 156 | 31 |
| Gabapentin | Gabapentin | 144 | 41 |
| Glimepiride | Glimepiride | 131 | 38 |
| Trazodone Hcl | Trazodone Hcl | 126 | 41 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 118 | 25 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 117 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 34 |
| Ketoconazole | Ketoconazole | 114 | 61 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 112 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 108 | 18 |
| Celecoxib | Celecoxib | 96 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 52 |
| Ibuprofen | Ibuprofen | 92 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 26 |
| Sertraline Hcl | Sertraline Hcl | 89 | 18 |
| Vascepa | Icosapent Ethyl | 88 | 16 |
| Hydrocortisone | Hydrocortisone | 83 | 39 |
| Ozempic | Semaglutide | 83 | 14 |
| Linzess | Linaclotide | 80 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 18 |
| Carvedilol | Carvedilol | 75 | 25 |
| Furosemide | Furosemide | 73 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 71 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 20 |
| Januvia | Sitagliptin Phosphate | 70 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 11 |
| Prednisone | Prednisone | 65 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 27 |
| Pregabalin | Pregabalin | 62 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 25 |
| Azithromycin | Azithromycin | 60 | 50 |
| Eliquis | Apixaban | 60 | 14 |
| Restasis | Cyclosporine | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 14 |
| Atenolol | Atenolol | 53 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Naproxen | Naproxen | 50 | 25 |
| Valsartan | Valsartan | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 46 | 19 |
| Xarelto | Rivaroxaban | 45 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Lorazepam | Lorazepam | 43 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 12 |
| Allopurinol | Allopurinol | 34 | 12 |
| Glipizide | Glipizide | 34 | 13 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 25 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 15 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 20 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 13 |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tretinoin | Tretinoin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Eucrisa | Crisaborole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sodium Fluoride | Fluoride (Sodium) | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | 11 |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $768.47 · 28 records | Phathom Pharmaceuticals, Inc. | BREZTRI, CREON, GEMTESA, JARDIANCE, Kerendia, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus, VOQUEZNA, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error